Steadybase.

Scribe Therapeutics, Inc.

Website Investor relations LinkedIn
  • SCTX · Nasdaq
  • Biological Products, (No Diagnostic Substances)
  • Alameda, CA
  • CIK 0001853921

Updated from SEC filings through

Top things to know

Executives

Scribe Therapeutics, Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Alameda, CA. It trades as SCTX on Nasdaq. Benjamin L. Oakes is President, CEO.

Five-year financials

We have no annual financials for this company yet.

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Benjamin L. Oakes
CEO I Scribe Therapeutics
President, CEO Form 4, July 27, 2026
David Parrot
CFO Scribe Therapeutics
Chief Financial Officer Form 4, July 27, 2026
Svetlana Lucas Chief Business Officer Form 4, July 27, 2026

What Scribe Therapeutics, Inc. does

We’re unlocking the future of medicine with CRISPR-based therapeutics that are safe and effective enough to transform everyone's lifetime risk for disease.

Company website description, 10-K for the year ending November 7, 2026

Shares and governance

Shares outstanding 18.9 million (as of November 6, 2026) 10-Q, November 12, 2026

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
July 28, 2026 Ventures LLC Avoro
Director
Buy 2,391,238 $36.3M Form 4, July 28, 2026
July 28, 2026 Behzad Aghazadeh
Director
Buy 2,391,238 $36.3M Form 4, July 28, 2026
July 28, 2026 Capital Advisors LLC Avoro
Director
Buy 2,391,238 $36.3M Form 4, July 28, 2026
July 27, 2026 Carl L. Gordon
Director
Buy 1,000,000 $15.0M Form 4, July 29, 2026
July 27, 2026 Capital GP VIII LLC OrbiMed
Director
Buy 1,000,000 $15.0M Form 4, July 29, 2026
July 27, 2026 Advisors Llc Orbimed
Director
Buy 1,000,000 $15.0M Form 4, July 29, 2026
July 23, 2026 David Parrot
Chief Financial Officer
Buy 2,666 $40K Form 4, July 27, 2026
July 23, 2026 Svetlana Lucas
Chief Business Officer
Buy 3,000 $45K Form 4, July 27, 2026

Recent 8-K events

Frequently asked questions about Scribe Therapeutics, Inc.

What does Scribe Therapeutics, Inc. do?
In its own words, from Item 1 of its 10-K: "We’re unlocking the future of medicine with CRISPR-based therapeutics that are safe and effective enough to transform everyone's lifetime risk for disease."
Who is the CEO of Scribe Therapeutics, Inc.?
Benjamin L. Oakes, President, CEO, as named in a 4 filed July 27, 2026.
Who is the CFO of Scribe Therapeutics, Inc.?
David Parrot, Chief Financial Officer, as named in a 4 filed July 27, 2026.
Where is Scribe Therapeutics, Inc. headquartered?
Alameda, CA.
What is Scribe Therapeutics, Inc.'s stock ticker?
SCTX on Nasdaq.
What industry is Scribe Therapeutics, Inc. in?
Biological Products, (No Diagnostic Substances), SIC code 2836.
What is Scribe Therapeutics, Inc.'s website?
scribetx.com. Investor relations: https://investors.scribetx.com/.
When does Scribe Therapeutics, Inc. report earnings next?
December 2, 2026. Source: pg_future_events.
Is Scribe Therapeutics, Inc. a public company?
Yes. Scribe Therapeutics, Inc. files with the SEC under CIK 0001853921 and trades as SCTX.
How many shares of Scribe Therapeutics, Inc. are outstanding?
18.9 million shares as of November 6, 2026, from its 10-Q filed November 12, 2026.
Have Scribe Therapeutics, Inc. insiders traded stock recently?
Since July 23, 2026, officers and directors reported 0 open-market sales and 8 purchases worth about $154M on Forms 4 and 5. The most recent: Ventures LLC Avoro (Director) bought 2,391,238 shares on July 28, 2026.